Frazier Life Sciences’ Post

One of the most interesting areas of investment at Blackstone is life sciences.  The need for capital and know-how to optimize clinical trials continues to grow and outpace the availability of capital. Here’s 5 key takeaways from Nick Galakatos who leads our life sciences business. 

McDermott Will & Emery’s inaugural Pharma and MedTech Services Investment Summit brings together C-suite executives, private equity professionals, investment bankers, and other industry leaders for a deep dive into the investment opportunities and emerging trends shaping pharma and device services. BGL’s Head of Healthcare & Life Sciences John Riddle is a featured panelist for a session entitled, “Clinical Trial Site Management Organizations,” on Thursday, May 2nd from 2 -2:40 p.m. PT. BGL’s Diagnostics, Research Tools & Medical Devices investment banking team has decades of experience advising companies across the diagnostics and device landscape. With this in-depth knowledge and background, we have provided capital formation, technology strategy, and medical device M&A strategy for a wide range of diagnostics, research tools, and device companies. To learn more about our experience and capabilities in the Pharma and MedTech Services sectors, including our most recent transactions, visit: https://lnkd.in/g3fVKzYp #Investmentbanking #MergersAndAcquisitions #Healthcare #MedicalDevice #Pharma

🚀 Join us for an exciting presentation and panel discussion exploring the dynamic biotech ecosystem in San Diego! 📅 Tuesday, June 18th 🕓 4:30 - 7:00 PM 📍The Alexandria at Torrey Pines, 10996 Torreyana Rd, San Diego, CA 92121 🔬 Our panel will feature four distinguished members from the local venture capital and institutional investment community, offering their insights into the San Diego life sciences industry. We will delve into the landscape of the industry, how companies secure funding, and how investors and advisors can tap into this pipeline of opportunities. 💡 Topics include: What do fund managers look for when evaluating prospective investments? What are the various funding stages of a typical biotech company? Key questions investors should ask at each stage of funding. The influential roles of leading academic and research institutions. How "Big Pharma" views and collaborates with smaller companies to enhance their therapeutic pipelines. Why San Diego is uniquely primed for life sciences companies. 🎤 Don’t miss out on this opportunity to learn from leaders in one of San Diego’s fastest-growing industries! Last call to register - https://cvent.me/mV9qoB

Eric Espinoza VP at Green Life Business, weighs in on the new opportunities arising in the cannabis space during the main stage M&A panel at Benzinga Cannabis's Capital Conference: There is a lot of consolidation in California, we believe there is opportunity in stressed environments. "Even though there are hard deals, there are also gems popping out in the West Coast, especially in California.” Espinoza calls these distressed companies “gems,” or companies that have called for offers because they need of capital. He mentioned that these situations might lead to picking up valuable companies for pennies on the dollar, noting that interesting investor spaces can be found on the West Coast, California, Nevada and the East Coast in New York, Florida and Ohio. Catch the fascinating full panel discussion: https://lnkd.in/g45B4wPU #benzinga #miami #industry #cannabis #benzingacannabisconference #capital #investing #cannabisindustry #leaders

On July 25, managing partner Jeny Maier will speak at the American Conference Institute's Women Leaders in Life Sciences Law Conference in Boston. Jeny will speak on the "Navigating Today’s Life Sciences M&A Landscape: Charting the Latest Trends and Challenges in Pharma and Biotech Dealmaking" panel. The discussion will include the recent growth of life sciences M&A, the areas of the life sciences market that are the biggest targets for investment in 2024, and the DOJ and FTC’s new “2023 Merger Guidelines,” including whether the new guidelines will impact or hinder M&A activity. Click here for more information or to register: https://lnkd.in/dEWmWsM #antitrust

Successful life sciences deal-making requires the ability to navigate the here and now while also trying to see around corners and predict the future. For those at BIO, join me tomorrow (June 5) for a deep dive into the current choppy waters of deal-making in the current markets, where I have the privilege of talking with Barbara Kosacz, Joseph Baroldi and Stacy Feld to share their insights and perspectives from decades of collective experience across various sectors of the life sciences and biotech industry, including roles as C-suite executives, investors, legal counsel, and board members in a range of life sciences companies and investment funds. https://lnkd.in/gz_ZKaBX

In the beginning of January, our international Life Sciences team, including Ross McNaughton, Adrian Toutoungi, Colin McCall, Dr. Stefanie Greifeneder, Niclas von Woedtke and Sarah Cole, attended the J.P. Morgan Healthcare Conference to connect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. Cautious optimism was the prevailing attitude amongst biotech CEOs and investors. Read more on the key themes of discussion at this year's conference, which we expect to be major topics throughout 2024: https://bit.ly/3unOLcU   #LifeSciences #TechInvestors #PrivateWealth 

Boston, the San Francisco Bay Area and San Diego are once again the top markets for life sciences commercial real estate in the U.S., with plenty of opportunities for growth as biotech readies for a comeback, according to a new report.

PE investments in life sciences peaked in 2021, when investors closed 695 PE transactions totaling $127.5 billion, according to PitchBook data. Interesting article on the 5 most active PE groups in life sciences. #kestersearchgroup Molly White Jones Michael Butler Kate Bahnmuller

The 23rd Annual Biotech in Europe Forum for Global Partnering & Investment (#Sachs_BEF), sponsored by Sachs Associates, is now in full swing in Basel, Switzerland. This global bio-pharma industry event is covering the major investment challenges for 2023 as well as partnership and alliance management and the outlook for 2024, with insight from key investors, analysts, and company executives. While there are challenges, there is a lot to be excited about, including promising new molecules and modalities. Yesterday, Dr. Hubert Birner, Managing Partner of TVM Capital Life Science participated in the roundtable, "Venture & Private Equity: Addressing Current Markets" with other high-profile experts, discussing fundraising and investing trends in the current financial climate plus a look at the future. Other panelists were: Robbie McLaren, Partner & Global Vice Chair of the Healthcare & Life Sciences Industry Group, Latham & Watkins LLP Thibaut Roulon, Senior Investment Director, Bpifrance Magne Stoknes, Principal, Novo Holdings A/S Cheryl Zimberlin, Investment Director, M Ventures The panelists discussed the collaboration between institutional investors and corporate venture funds, how funds can best allocate what they amassed during the COVID-19 pandemic to previously overfunded start-ups, how precision finance is demanding more from companies, and many other timely topics. #VC #lifescience